Abstract | OBJECTIVE: MATERIALS AND METHODS: RESULTS: Eighteen eyes from 16 patients were finally included. Patients were followed up for a minimum of 6 months. The mean age at initial treatment was 56.4 years. Mean refractive error was -13.3 diopters. Regarding FAG, all neovascular membranes were classical and sub or juxtafoveal localised. At the end of the sixth month after treatment fourteen eyes (77.7%) showed better visual acuity ranging from one or more lines on the Snellen chart, eleven eyes (61.1%) improved two lines or more, three eyes (16.6%) did not show any change and one eye (5.5%) worsened by one line. At 6 months the mean best-corrected visual acuity improved from 0.25 to 0.46 (p= 0.001). The mean central macular thickness decreased from 344.9 to 212.6 (p=0.015). CONCLUSIONS:
Ranibizumab may be a good therapeutic option as treatment for choroidal neovascularisation due to pathological myopia; it improved visual acuity and anatomical features, even in non-responders to photodynamic therapy (Arch Soc Esp Oftalmol 2009; 84: 507-514).
|
Authors | C Torrón, C Egea, E Ferrer, O Ruiz, F M Honrubia |
Journal | Archivos de la Sociedad Espanola de Oftalmologia
(Arch Soc Esp Oftalmol)
Vol. 84
Issue 10
Pg. 507-14
(Oct 2009)
ISSN: 1989-7286 [Electronic] Spain |
Vernacular Title | Tratamiento de membranas neovasculares miópicas con Ranibizumab. |
PMID | 19902395
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Ranibizumab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Choroidal Neovascularization
(drug therapy, etiology)
- Female
- Humans
- Macular Degeneration
- Male
- Middle Aged
- Myopia
(complications)
- Ranibizumab
- Retrospective Studies
|